で組織・契約価格をご覧ください。
サイズを選択してください
表示を変更する
この商品について
実験式(ヒル表記法):
C14H17N3O3S · xHCl
CAS番号:
分子量:
307.37 (free base basis)
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77
Assay:
≥98% (HPLC)
Form:
liquid
Storage condition:
OK to freeze, protect from light
Quality Segment
assay
≥98% (HPLC)
form
liquid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, protect from light
shipped in
wet ice
storage temp.
−20°C
SMILES string
[S](=O)(=O)(N3CCNCCC3)c1c2c([c]([nH]cc2)=O)ccc1.Cl
InChI
1S/C14H17N3O3S.ClH/c18-14-12-3-1-4-13(11(12)5-7-16-14)21(19,20)17-9-2-6-15-8-10-17;/h1,3-5,7,15H,2,6,8-10H2,(H,16,18);1H
InChI key
XWWFOUVDVJGNNG-UHFFFAOYSA-N
General description
A cell-permeable, hydroxylated metabolite of HA 1077 (Fasudil; Cat. No. 371970) that displays anti-anginal properties. Acts as an ATP-competitive and a reversible inhibitor of Rho-kinase (IC50 = 0.9 and 1.8 µM using a peptide and MLC as substrate, respectively) with ~100-fold greater selectivity over MLCK, MRCKβ, and PKC. Reported to inhibit the Rho kinase-mediated contraction both in vitro and in vivo.
Biochem/physiol Actions
Cell permeable: yes
Primary Target
Rho-kinase
Rho-kinase
Product competes with ATP.
Reversible: yes
Target IC50: 0.9 and 1.8 µM against Rho-kinase using a peptide and MLC as substrate, respectively
Packaging
Packaged under inert gas
Physical form
A 10 mM (2 mg/582 µl) solution in H₂O.
Other Notes
Ito, K., et al. 2003. J. Physiol.546, 823.
Takemoto, M., et al. 2002. Circulation106, 57.
Shimokawa, H., et al. 1999. Cardiovasc. Res.43, 1029.
Takemoto, M., et al. 2002. Circulation106, 57.
Shimokawa, H., et al. 1999. Cardiovasc. Res.43, 1029.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Harmful (C)
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
保管分類
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
試験成績書(COA)
製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。
